Bristol-Myers Squibb (BMS) and Flatiron Health have expanded their relationship with a three-year collaboration agreement. BMS will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. With the expanded collaboration, the two companies intend to form a joint scientific advisory board to advance the use of RWE for regulatory decision ...